MDxHealth’s (MDXH) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of MDxHealth (NASDAQ:MDXH) in a research note released on Tuesday,Benzinga reports. The firm currently has a $7.00 price target on the stock.

A number of other research firms also recently weighed in on MDXH. Lake Street Capital raised their price target on MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen raised shares of MDxHealth to a “hold” rating in a research report on Saturday, August 30th. TD Cowen upped their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MDxHealth in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

MDxHealth Trading Up 0.3%

NASDAQ:MDXH opened at $3.48 on Tuesday. The stock’s fifty day moving average price is $3.85 and its two-hundred day moving average price is $3.35. The company has a market cap of $164.57 million, a P/E ratio of -5.44 and a beta of 1.59. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.14 and a quick ratio of 1.02. MDxHealth has a 1 year low of $1.35 and a 1 year high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. The company had revenue of $27.43 million for the quarter, compared to analysts’ expectations of $24.11 million. As a group, analysts expect that MDxHealth will post -1.15 EPS for the current year.

Institutional Trading of MDxHealth

Several hedge funds have recently made changes to their positions in MDXH. AWM Investment Company Inc. boosted its holdings in shares of MDxHealth by 10.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock worth $7,414,000 after purchasing an additional 499,992 shares during the period. Kennedy Capital Management LLC bought a new position in shares of MDxHealth during the third quarter valued at approximately $1,826,000. Mink Brook Asset Management LLC bought a new stake in MDxHealth during the third quarter valued at about $743,000. Delta Investment Management LLC increased its position in shares of MDxHealth by 459.1% during the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock worth $270,000 after purchasing an additional 156,100 shares in the last quarter. Finally, Panoramic Capital LLC acquired a new stake in MDxHealth in the 3rd quarter worth approximately $721,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.